Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
